Therapeutic Apheresis Market Expected to Reach $2.8 Billion by 2035

According to a new report published by Allied Market Research, titled, “Therapeutic Apheresis Market," The therapeutic apheresis market size was valued at $1.3 billion in 2023, and is estimated to reach $2.8 billion by 2035, growing at a CAGR of 6.7% from 2024 to 2035. Therapeutic apheresis is a medical procedure in which blood is drawn from a patient, processed to remove specific components, and then returned to the body. This treatment is typically used to remove harmful substances such as antibodies, toxins, or abnormal cells that contribute to various medical conditions. It is commonly employed in the management of autoimmune diseases, certain types of cancer, and conditions such as nephrotic syndrome or hyperlipidemia. The procedure helps in reducing disease symptoms and improving the overall health of the patient by selectively targeting and eliminating harmful substances from the bloodstream.

The therapeutic apheresis market trends includes increase in prevalence of chronic and autoimmune diseases such as rheumatoid arthritis, multiple sclerosis, and systemic lupus erythematosus often require apheresis treatments to manage symptoms and improve quality of life. For instance, according to the World Health Organization (WHO), over 1.8 million people had multiple sclerosis globally in 2023. As the global incidence of these diseases rises, the demand for therapeutic apheresis is expected to grow.  

However, therapeutic apheresis requires specialized machines, skilled professionals, and ongoing maintenance, making it an expensive treatment option, which can limit its accessibility, especially in low-resource settings. In addition, the procedure has side effects, such as infections, bleeding, or allergic reactions, which may deter patients or healthcare providers from opting for it. On the other hand, rise in technological advancements in apheresis technology, such as automation and improved filtration techniques provides therapeutic apheresis market opportunity. 

The therapeutic apheresis market size is segmented into product type, procedure type, application, end user, and region. On the basis of product type, the market is classified into devices, consumables, and software. The consumables segment accounted for the largest share in 2023 and is expected to register the highest CAGR during the forecast period, owing to necessity for single-use disposables in each procedure, ensuring patient safety and minimizing contamination risks. The rising prevalence of chronic diseases led to an increased number of apheresis procedures, further boosting the demand for consumables.

On the basis of procedure type, the market is classified into therapeutic plasma exchange (TPE), photopheresis, low density lipid removal, stem cell harvest, and other procedures. The therapeutic plasma exchange (TPE) segment accounted for the largest therapeutic apheresis market share in 2023, owing to its widespread use in treating a variety of autoimmune and neurological disorders. TPE effectively removes harmful antibodies, immune complexes, and toxins from the blood, providing significant therapeutic benefits for patients with conditions like lupus, myasthenia gravis, and vasculitis. However, the photopheresis is expected to register the highest CAGR during the forecast period. This is attributed to increasing prevalence of autoimmune diseases and cutaneous T-cell lymphoma. Advancements in photopheresis technology and favorable reimbursement policies further contribute to the therapeutic apheresis market growth. 

On the basis of application, the market is classified into hematology, neurology, oncology, and others. The hematology segment accounted for the largest therapeutic apheresis market share in 2023 and is expected to register the highest CAGR during the forecast period. This is attributed to rise in prevalence of blood-related disorders such as sickle cell anemia, hemophilia, and leukemia. Therapeutic apheresis is commonly used in managing these conditions by removing abnormal blood components or toxins and improving patient outcomes. Rise in adoption of apheresis therapies for blood disorders, combined with advancements in treatment technologies, has contributed to the hematology segment’s dominance in the market.

On the basis of end user, the market is categorized into hospitals, blood centers, and others. The hospitals segment accounted for the largest share in 2023, owing to rise in demand for therapeutic apheresis procedures in clinical settings. Hospitals provide the necessary infrastructure, specialized equipment, and skilled healthcare professionals to perform complex treatments such as apheresis.

Region-wise, North America dominated the therapeutic apheresis industry in 2023, owing to the region's advanced healthcare infrastructure, high adoption of advanced apheresis technologies, and strong regulatory framework supporting blood component therapies. The presence of well-established hospitals and specialized centers equipped with the latest apheresis devices contributed to the therapeutic apheresis market growth. However, Asia-Pacific is anticipated to witness notable growth during the therapeutic apheresis market forecast period owing to rise in prevalence of chronic and autoimmune diseases, increase in healthcare investments, and improving healthcare infrastructure in the region. Rise in awareness of advanced treatment options like therapeutic apheresis, along with rise in availability of specialized medical centers , is expected to drive the therapeutic apheresis industry growth.

Key findings of the study 

• On the basis of product type, the consumables segment was largest contributor to the market in 2023. 
• On the basis of procedure type, the therapeutic plasma exchange (TPE) segment was largest contributor to the market in 2023.
• On the basis of application, the hematology segment was largest contributor to the market in 2023.
• On the basis of end user, the hospitals segment was largest contributor to the market in 2023.
• Region-wise, North America generated the largest revenue in 2023. However, Asia-Pacific is anticipated to grow at the highest CAGR during the forecast period.